Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIq-ai Ltd Regulatory News (IQAI)

Share Price Information for Iq-ai Ltd (IQAI)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1.60
Bid: 1.50
Ask: 1.70
Change: 0.00 (0.00%)
Spread: 0.20 (13.333%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 1.60
IQAI Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Five Year NCI Award Grant to IB

6 Apr 2021 07:00

RNS Number : 4529U
IQ-AI Limited
06 April 2021
 

IQ-AI Ltd

("IQ-AI" or the "Company")

Five Year NCI Award Grant to IB

 

The Company's subsidiary, Imaging Biometrics, LLC (IB), has received another award from the US National Cancer Institute (NCI). Approximately $3 million in funding begins on 15 April and is in collaboration with Professor Kathleen Schmainda, PhD, the grant's Principal Investigator (PI) at the Medical College of Wisconsin (MCW). The award is the third NCI grant IB has received within a two year period. As a subawardee on the grant, IB will use the funds to accelerate the development and commercialisation of IB CAD™.

 

IB CAD combines multi-parameter magnetic resonance (MR) data and artificial intelligence (AI) technology to identify areas of infiltrating brain tumour cells in non-contrast enhancing regions. The current paradigm is to wait until the cells grow into a tumour large enough to be visualised on standard imaging and/or treat all areas in a similar way, which together may result in delayed or suboptimal treatment targeting. Thus, the Directors of IQ-AI believe that IB CAD's ability to "detect the undetectable" may offer early detection and, thereby, giving current treatment therapies a better chance of success. Moreover, the Directors consider that the technology has the potential to disrupt the way surgery is performed, how radiation treatments are planned, and how treatment therapy is assessed.

 

Trevor Brown, IQ-AI CEO commented "We continue to advance the field in brain tumour imaging and understanding. This grant underscores the scientific merits of the technology and helps pave the way towards commercialisation."

 

The Directors of the Company accept responsibility for the contents of this announcement.

-ENDS-

For further information, please contact:

IQ-AI Limited

Trevor Brown/Vinod Kaushal/Qu Li/Michael Schmainda

Tel: 020 7469 0930

Peterhouse Capital Limited (Financial Adviser and Broker)

Lucy Williams/Heena Karani

Tel: 020 7220 9797

 

 

ABOUT Imaging Biometrics™, LLC

Imaging Biometrics, a subsidiary of IQ-AI Limited (LON:IQAI), develops and provides visualisation and analytical solutions that enable clinicians to better diagnose and treat disease with greater confidence. Through close collaboration with top researchers and clinicians, sophisticated advancements are translated into platform-independent and automated software plug-ins which can extend the base functionality of workstations, imaging systems, PACS, or medical viewers. By design, IB's advanced visualisation software seamlessly integrates into routine workflows. For more information about Imaging Biometrics, visit the company's website at www.imagingbiometrics.com.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
STRFFFLISEIEIIL
Date   Source Headline
30th Apr 20184:25 pmRNSFinal Results
11th Apr 20187:00 amRNSIMAGING BIOMETRICS ANNOUNCES PARTNERSHIP
29th Mar 20182:52 pmRNSTotal Voting Rights
13th Mar 201810:54 amRNSTotal Voting Rights
13th Mar 20187:40 amRNSAcquisition of Imaging Biometrics
6th Mar 20187:00 amRNSStoneChecker signs agreement with Korea ISG
8th Feb 20181:44 pmRNSPotential Acquisition
8th Feb 20189:05 amRNSSecond Price Monitoring Extn
8th Feb 20189:00 amRNSPrice Monitoring Extension
11th Dec 20177:00 amRNSCE marked release of StoneChecker® Software
6th Nov 20174:40 pmRNSSecond Price Monitoring Extn
6th Nov 20174:35 pmRNSPrice Monitoring Extension
26th Oct 20177:00 amRNSUpdate on Business Operations
9th Oct 20172:33 pmRNSHolding(s) in Company
18th Sep 20177:00 amRNSUpdate on Product Development and Warrant Exercise
4th Sep 20179:49 amRNSStone Checker Update
30th Aug 201710:04 amRNSHolding(s) in Company
17th Aug 20177:01 amRNSDirector Dealings
17th Aug 20177:00 amRNSHalf-year Report
14th Aug 201710:12 amRNSHolding(s) in Company
27th Jul 20174:40 pmRNSSecond Price Monitoring Extn
27th Jul 20174:35 pmRNSPrice Monitoring Extension
11th Jul 20177:00 amRNSUpdate on Operations
3rd Jul 20177:00 amRNSConversion of Convertible Loan Notes into Equity
27th Jun 20174:40 pmRNSSecond Price Monitoring Extn
27th Jun 20174:35 pmRNSPrice Monitoring Extension
16th Jun 20177:00 amRNSReadmission to the London Stock Exchange
15th Jun 20171:42 pmRNSResult of Annual General Meeting & General Meeting
19th May 20177:00 amRNSProspectus, Placing & Expected Readmission
28th Apr 20173:12 pmRNSFinal Results
27th Feb 201711:51 amRNSHolding(s) in Company
20th Jan 20171:30 pmRNSAppointment of Non-Executive Director
26th Aug 201612:06 pmRNSHalf-year Report
30th Jun 201612:58 pmRNSProposed Acquisition and Suspension of Listing
31st May 20161:33 pmRNSHolding(s) in Company
27th May 201611:39 amRNSResult of AGM
5th May 20164:15 pmRNSHolding(s) in Company
4th May 20167:00 amRNSNotice of AGM
20th Apr 20167:00 amRNSHolding(s) in Company
20th Apr 20167:00 amRNSFinal Results
5th Apr 201610:48 amRNSStatement re Update
20th Nov 20157:00 amRNSBoard changes, corporate update, issue of CLN
21st Oct 20157:00 amRNSAppointment of Financial Adviser and Broker
25th Aug 20153:29 pmRNSHalf Yearly Report
16th Jul 201511:17 amRNSHolding(s) in Company
16th Jul 201511:15 amRNSHolding(s) in Company
13th Jul 20152:57 pmRNSConversion of Convertible Loan Notes
29th May 20154:21 pmRNSResult of AGM
1st May 201511:28 amRNSNotice of AGM and Transfer of CLN to Director-Rep
30th Apr 20156:28 pmRNSNotice of AGM and Transfer of CLN to Director

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.